跳转至内容
Merck
CN

SML3451

Maytansine

≥95% (HPLC)

别名:

MTS, Maitansine, Maysanine, Maytansin, N-Acetyl-N-methyl-L-alanine [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl ester, NSC 153858

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C34H46ClN3O10
化学文摘社编号:
35846-53-8
分子量:
692.20
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD28127038

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Maytansine, ≥95% (HPLC)

InChI

1S/C34H46ClN3O10/c1-18-11-10-12-26(45-9)34(43)17-25(46-32(42)36-34)19(2)30-33(5,48-30)27(47-31(41)20(3)37(6)21(4)39)16-28(40)38(7)23-14-22(13-18)15-24(44-8)29(23)35/h10-12,14-15,19-20,25-27,30,43H,13,16-17H2,1-9H3,(H,36,42)/b12-10+,18-11+/t19-,20+,25+,26-,27+,30+,33+,34+/m1/s1

SMILES string

O[C@]([C@@H](/C=C/C=C(CC1=CC2=C(C(OC)=C1)Cl)\C)OC)(C[C@H](O3)[C@H]([C@H]4[C@](C)([C@H](CC(N2C)=O)OC([C@@H](N(C)C(C)=O)C)=O)O4)C)NC3=O

InChI key

WKPWGQKGSOKKOO-RSFHAFMBSA-N

assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

100

相关类别

Biochem/physiol Actions

Cytotoxic agent, microtubule inhibitor

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Muta. 2 - Repr. 2 - STOT RE 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000200557
0000200558
0000189005
0000189005
0000200558

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Grégory Menchon et al.
Nature communications, 9(1), 2106-2106 (2018-05-31)
Microtubule-targeting agents (MTAs) like taxol and vinblastine are among the most successful chemotherapeutic drugs against cancer. Here, we describe a fluorescence anisotropy-based assay that specifically probes for ligands targeting the recently discovered maytansine site of tubulin. Using this assay, we have
Zhengyang Jiang et al.
Bioconjugate chemistry, 29(9), 2920-2926 (2018-08-14)
This study was undertaken to target cell surface receptors other than the ones typically associated with breast cancer {estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)}. It was also launched to use small molecules
Maxine Bauzon et al.
Oncoimmunology, 8(4), e1565859-e1565859 (2019-03-25)
Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20-40% of patients to generate anti-tumor immune responses. Combination treatment approaches with chemotherapeutic drugs may enable responses in the remaining patient cohorts. In this regard

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持